Literature DB >> 29769455

Tenascin C: A Potential Biomarker for Predicting the Severity of Coronary Atherosclerosis.

Wen Gao1, Jian Li1, Huanchun Ni1, Haiming Shi1, Zhiyong Qi2, Shouguo Zhu3, Chuanming Hao4, Qionghong Xie4, Xinping Luo1, Kun Xie1.   

Abstract

AIMS: Coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide and one of the greatest threats to public health. Tenascin C (TNC) is an extracellular matrix glycoprotein that is found in low concentrations in normal tissues and is enhanced by a range of cardiovascular pathologies. This study aimed to evaluate the value of TNC in assessing the severity of atherosclerosis measured by the Gensini score.
METHODS: A total of 157 patients with chest pains who underwent selective coronary angiography for suspected coronary atherosclerosis were enrolled. The patients were divided into the CAD group and non-CAD group according to symptoms and angiography. Demographic data and laboratory analyses were collected.
RESULTS: The mean TNC level was significantly higher in the CAD group than in the non-CAD group (p<0.001). A significant positive correlation between TNC levels and Gensini score (p<0.01, r=0.672) was found. ROC curve analysis demonstrated that the cutoff value for TNC at 89.48 ng/mL was well differentiated in the CAD and non-CAD groups. Furthermore, TNC was also a good predictor for a higher Gensini score (the third tertile) in the ROC curve analysis. When the cutoff was accepted as 100.91 ng/mL, the sensitivity and specificity were 82.7% and 79%, respectively.
CONCLUSION: A significant relationship was found between the Gensini score and serum TNC level. TNC levels can be considered in risk assessments for CAD before angiography.

Entities:  

Keywords:  Atherosclerosis; Coronary artery disease; Gensini score; Tenascin C

Mesh:

Substances:

Year:  2018        PMID: 29769455      PMCID: PMC6308263          DOI: 10.5551/jat.42887

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  26 in total

1.  Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction.

Authors:  Akira Sato; Kazutaka Aonuma; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; Mitsuaki Isobe; Daisuke Kawase; Noriaki Kinoshita; Yoshio Yazaki; Michiaki Hiroe
Journal:  J Am Coll Cardiol       Date:  2006-05-04       Impact factor: 24.094

2.  Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo.

Authors:  Tobias von Lukowicz; Michela Silacci; Matthias T Wyss; Eveline Trachsel; Christine Lohmann; Alfred Buck; Thomas F Lüscher; Dario Neri; Christian M Matter
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

3.  Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease.

Authors:  Jan Henrik Hörstrup; Mathias Gehrmann; Birgit Schneider; Angela Plöger; Peter Froese; Thea Schirop; Dieter Kampf; Ulrich Frei; Rainer Neumann; Kai-Uwe Eckardt
Journal:  Nephrol Dial Transplant       Date:  2002-06       Impact factor: 5.992

4.  Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque.

Authors:  K Wallner; C Li; P K Shah; M C Fishbein; J S Forrester; S Kaul; B G Sharifi
Journal:  Circulation       Date:  1999-03-16       Impact factor: 29.690

5.  Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Stephen Cook; Michael Weitzman; Peggy Auinger; Michael Nguyen; William H Dietz
Journal:  Arch Pediatr Adolesc Med       Date:  2003-08

6.  Tenascins are associated with lipid rafts isolated from mouse brain.

Authors:  Joachim Kappler; Stephan L Baader; Sebastian Franken; Penka Pesheva; Karl Schilling; Uwe Rauch; Volkmar Gieselmann
Journal:  Biochem Biophys Res Commun       Date:  2002-06-14       Impact factor: 3.575

7.  Mechanical properties of the extracellular matrix alter expression of smooth muscle protein LPP and its partner palladin; relationship to early atherosclerosis and vascular injury.

Authors:  Li Jin; Nicole E Hastings; Brett R Blackman; Avril V Somlyo
Journal:  J Muscle Res Cell Motil       Date:  2009-02-10       Impact factor: 2.698

8.  Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes.

Authors:  Kajiwara Kenji; Ueda Hironori; Yamamoto Hideya; Imazu Michinori; Hayashi Yasuhiko; Kohno Nobuoki
Journal:  Circ J       Date:  2004-03       Impact factor: 2.993

Review 9.  The regulation of tenascin expression by tissue microenvironments.

Authors:  Richard P Tucker; Ruth Chiquet-Ehrismann
Journal:  Biochim Biophys Acta       Date:  2008-12-31

10.  Gene expression phenotypes of atherosclerosis.

Authors:  David Seo; Tao Wang; Holly Dressman; Edward E Herderick; Edwin S Iversen; Chunming Dong; Korkut Vata; Carmelo A Milano; Fabio Rigat; Jennifer Pittman; Joseph R Nevins; Mike West; Pascal J Goldschmidt-Clermont
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-05       Impact factor: 8.311

View more
  9 in total

1.  Concomitant elevated serum levels of tenascin, MMP-9 and YKL-40, suggest ongoing remodeling of the heart up to 3 months after cardiac surgery after normalization of the revascularization markers.

Authors:  Da Liu; Danyal Ghani; Justin Wain; Wilson Y Szeto; Krzysztof Laudanski
Journal:  Eur J Med Res       Date:  2022-10-21       Impact factor: 4.981

2.  Serum Tenascin-C and Alarin Levels Are Associated with Cardiovascular Diseases in Type 2 Diabetes Mellitus.

Authors:  Mingming Li; Mengjiao Wu; Hua Zhu; Yulin Hua; Zijun Ma; Jiayi Yao; Bin Feng; Bimin Shi
Journal:  Int J Endocrinol       Date:  2022-04-21       Impact factor: 2.803

3.  Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.

Authors:  Barnabas Gellen; Nathalie Thorin-Trescases; Eric Thorin; Elise Gand; Philippe Sosner; Sonia Brishoual; Vincent Rigalleau; David Montaigne; Vincent Javaugue; Yann Pucheu; Philippe Gatault; Xavier Piguel; Samy Hadjadj; Pierre-Jean Saulnier
Journal:  Diabetologia       Date:  2020-02-10       Impact factor: 10.122

4.  The Role of Tenascin C in Cardiac Reverse Remodeling Following Banding-Debanding of the Ascending Aorta.

Authors:  Mireia Perera-Gonzalez; Attila Kiss; Philipp Kaiser; Michael Holzweber; Felix Nagel; Simon Watzinger; Eylem Acar; Petra Lujza Szabo; Inês Fonseca Gonçalves; Lukas Weber; Patrick Michael Pilz; Lubos Budinsky; Thomas Helbich; Bruno Karl Podesser
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 5.  The Roles of Tenascins in Cardiovascular, Inflammatory, and Heritable Connective Tissue Diseases.

Authors:  Ken-Ichi Matsumoto; Hiroki Aoki
Journal:  Front Immunol       Date:  2020-12-01       Impact factor: 7.561

6.  Evaluation of the serum levels of Mannose binding lectin-2, tenascin-C, and total antioxidant capacity in patients with coronary artery disease.

Authors:  Hamed Mehri; Naser Aslanabadi; Alireza Nourazarian; Behrouz Shademan; Fatemeh Khaki-Khatibi
Journal:  J Clin Lab Anal       Date:  2021-09-07       Impact factor: 2.352

7.  Cardiovascular changes after pneumonia in a dual disease mouse model.

Authors:  Benjamin Bartlett; Herbert P Ludewick; Shipra Verma; Vicente F Corrales-Medina; Grant Waterer; Silvia Lee; Girish Dwivedi
Journal:  Sci Rep       Date:  2022-07-01       Impact factor: 4.996

8.  MiR-495-3p depletion contributes to myocardial ischemia/reperfusion injury in cardiomyocytes by targeting TNC.

Authors:  Wei Song; Naiyan Qiu
Journal:  Regen Ther       Date:  2022-09-12       Impact factor: 3.651

9.  Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.

Authors:  Yukako Yoshikane; Yoshiaki Okuma; Tatsuki Miyamoto; Junichi Hashimoto; Ryuji Fukazawa; Taichi Kato; Atsuhito Takeda; Kenji Suda; Takeji Matsushita; Michiaki Hiroe; Kyoko Imanaka-Yoshida
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-05       Impact factor: 3.054

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.